individual that Tecentriq Dosage Generic name: atezolizumab 1200mg in 20mL Dosage form: injection, solution Overview Side Effects Dosage Professional Interactions More Pregnancy Warnings User Reviews Support Group Q & A Pricing & Coupons The information at Drugs.com is not a substitute for medical advice. Always consult your doctor or pharmacist. Recommended Dosing The recommended dose of TECENTRIQ is 1200 mg administered as an intravenous infusion over 60 minutes every 3 weeks until disease progression or unacceptable toxicity. If the first infusion is tolerated, all subsequent infusions may be delivered over 30 minutes. Do not administer TECENTRIQ as an intravenous push or bolus. Dose Modifications No dose reductions of TECENTRIQ are recommended. Withhold TECENTRIQ for any of the following: Grade 2 pneumonitis [see Warnings and Precautions (5.1) ] Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) greater than 3 and up to 5 times upper limit of normal (ULN) or total bilirubin greater than 1.5 and up to 3 times ULN [see Warnings and Precautions (5.2) ] Grade 2 or 3 diarrhea or colitis [see Warnings and Precautions (5.3) ] Symptomatic hypophysitis, adrenal insufficiency, hypothyroidism, hyperthyroidism, or Grade 3 or 4 hyperglycemia [see Warnings and Precautions (5.4) ] Grade 2 ocular inflammatory toxicity [see Warnings and Precautions (5.5) ] Grade 2 or 3 pancreatitis, or Grade 3 or 4 increases in amylase or lipase levels (greater than 2.0 times ULN) [see Warnings and Precautions (5.5) ] Grade 3 or 4 infection [see Warnings and Precautions (5.6) ] Grade 2 infusion-related reactions [see Warnings and Precautions (5.7) ] Grade 3 rash TECENTRIQ may be resumed in patients whose adverse reactions recover to Grade 0 1. Permanently discontinue TECENTRIQ for any of the following: Grade 3 or 4 pneumonitis [see Warnings and Precautions (5.1) ] AST or ALT greater than 5 times ULN or total bilirubin greater than 3 times ULN [see Warnings and Precautions (5.2) ] Grade 4 diarrhea or colitis [see Warnings and Precautions (5.3) ] Grade 4 hypophysitis [see Warnings and Precautions (5.4) ] Myasthenic syndrome/myasthenia gravis, Guillain-Barré or meningoencephalitis (all grades) [see Warnings and Precautions (5.5) ] Grade 3 or 4 ocular inflammatory toxicity [see Warnings and Precautions (5.5) ] Grade 4 or any grade of recurrent pancreatitis [see Warnings and Precautions (5.5) ] Grade 3 or 4 infusion-related reactions [see Warnings and Precautions (5.7) ] Grade 4 rash Preparation and Administration Preparation Visually inspect drug product for particulate matter and discoloration prior to administration whenever solution and container permit. TECENTRIQ is a colorless to slightly yellow solution. Discard the vial if the solution is cloudy, discolored, or visible particles are observed. Do not shake the vial. Prepare the solution for infusion as follows: Withdraw 20 mL of TECENTRIQ from the vial. Dilute into a 250 mL polyvinyl chloride (PVC), polyethylene (PE), or polyolefin (PO) infusion bag containing 0.9% Sodium Chloride Injection, USP. Dilute with 0.9% Sodium Chloride Injection only. Mix diluted solution by gentle inversion. Do not shake. Discard used or empty vials of TECENTRIQ. Storage of Infusion Solution This product does not contain a preservative. Administer immediately once prepared. If diluted TECENTRIQ infusion solution is not used immediately, it can be stored either: At room temperature for no more than 6 hours from the time of preparation. This includes room temperature storage of the infusion in the infusion bag and time for administration for infusion. Under refrigeration at 2 C 8 C (36 F 46 F) for no more than 24 hours. Do not freeze. Do not shake. Administration Administer the initial infusion over 60 minutes through an intravenous line with or without a sterile, non-pyrogenic, low-protein binding in-line filter (pore size of 0.2 0.22 micron). If the first infusion is tolerated, all subsequent infusions may be delivered over 30 minutes. Do not co-administer other drugs through the same intravenous line. Next Professional Print this page Add to My Med List More about Tecentriq (atezolizumab) Side Effects During Pregnancy Dosage Information Drug Interactions Support Group Pricing & Coupons En Español 1 Review Add your own review/rating Drug class: Anti-PD-1 monoclonal antibodies Consumer resources Tecentriq Tecentriq (Advanced Reading) Professional resources Tecentriq (AHFS Monograph) Tecentriq (FDA) Related treatment guides Bladder Cancer Non-Small Cell Lung Cancer Urothelial Carcinoma Drug Status Rx Availability Prescription only N/A CSA Schedule Not a controlled drug Approval History Drug history at FDA Manufacturer Genentech, Inc. Drug Class Anti-PD-1 monoclonal antibodies Related Drugs Non-Small Cell Lung Cancer Avastin , methotrexate , Taxol , Opdivo , cisplatin , Taxotere , Tarceva , Keytruda , More... Bladder Cancer cisplatin , Adriamycin , doxorubicin , mitomycin , atezolizumab , thiotepa , Platinol , Mutamycin , More... Urothelial Carcinoma Opdivo , Keytruda , nivolumab , pembrolizumab , atezolizumab , Imfinzi , avelumab , durvalumab , More... Tecentriq Rating 1 User Review 1 User Review Not Rated - Be the first! a petroleum
life-style Tecentriq Dosage enough
EmoticonEmoticon